Evidence map›Paper›PMID 34341833›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2022

Zoledronic acid and bone health in older adults with cognitive impairment.

B M Churilla, S Perera, S L Greenspan, N M Resnick, M P Kotlarczyk

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

B M ChurillaDivision of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
S PereraDivision of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
S L GreenspanDivision of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
N M ResnickDivision of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
M P KotlarczykDivision of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. mpk38@pitt.edu.ORCID http://orcid.org/0000-0002-5846-8461
University of Pittsburgh · US

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Caterina Rosano · 2004 to 2026
$28.6M
Pitt Integrated Clinical and Geroscience Research Training ProgramT32AG021885 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Aditi U Gurkar · 2003 to 2026
$6.7M
Maintenance of Skeletal Integrity in Frail EldersR01AG028086 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREENSPAN, SUSAN L · 2007 to 2013
$3.2M
NIA NIH HHS P30 AG024827NIA NIH HHS R01 AG028086NIA NIH HHS T32 AG021885
6 · The paper itself

Abstract

Fracture prevention in cognitively impaired individuals is lacking. This work highlights the benefits of zoledronic acid on bone health in cognitively impaired older adults. Demonstrating benefits of therapy may increase treatment uptake and reduce fracture risk in this group.

introductionOsteoporosis has detrimental consequences for frail older adults. The effects on those with both osteoporosis and cognitive impairment are compounded due to increased risk of falls and changes in mobility, both of which can lead to fracture. However, there are limited data on treatment benefits for osteoporotic individuals with cognitive impairment.

methodsThis post hoc, secondary analysis of data from a randomized, double-blind, placebo-controlled clinical trial of single-dose zoledronic acid included 179 women age ≥ 65 years residing in assisted living facilities or nursing homes, 43 of whom had mild to severe cognitive impairment. We assessed bone mineral density (BMD) of the total hip, femoral neck, and lumbar spine by dual-energy x-ray absorptiometry and serum bone turnover markers (C-terminal telopeptide of type I collagen and procollagen type I N propeptide) at 6 and 12 months.

resultsIn participants with cognitive impairment, those who received zoledronic acid had 4.3% greater BMD at the total hip (p=.005) and 5.3% greater BMD at the femoral neck (p<.001) after 12 months compared to those in the placebo group. Bone turnover markers demonstrated significant decreases at 6 months in those with cognitive impairment who received active treatment compared to the placebo group. Improvements in bone health measures with zoledronic acid were similar to those seen in participants without cognitive impairment.

conclusionZoledronic acid improves bone health in frail older women with cognitive impairment similar to those without impairment. Further studies are warranted to assess the benefit for fracture reduction in this undertreated population.

Indexed as

Bone Density Conservation AgentsCognitive DysfunctionAgedBone DensityBone RemodelingCollagen Type IDiphosphonatesDouble-Blind MethodFemaleFemur NeckHumansImidazolesZoledronic AcidBone Density Conservation AgentsCollagen Type IDiphosphonatesImidazolesProcollagen Type IZoledronic AcidBone densityCognitive impairmentOsteoporosisZoledronic acid

Identifiers

PMID34341833
PMCPMC8758516
OpenAlexW3189221530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.